sunvozertinib

FDA grants breakthrough status to Dizal’s sunvozertinib
Pharmaceutical Business Review
Mon, 04/8/24 - 11:54 am
Dizal Pharmaceutical
FDA
non-small cell lung cancer
sunvozertinib